Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03116139 · ClinicalTrials.gov registry record · NA

Acute Kidney Injury in Patients Undergoing Contrast Exposure: VQ vs. CT

A NA study, sponsored by Indiana University.

Terminated
Registry status
NA
Development phase
253
Enrollment target

NCT03116139: Clinical Trial NA study, sponsored by Indiana University.

NCT03116139 is a NA study that was terminated before completion, run by Indiana University. The registered enrollment target is 253 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03116139, a NA study, was terminated before completion, sponsored by Indiana University.

TERMINATED
Registry status
NA
Development phase
253 participants
Enrollment target

Study Summary

Both, CT scans and VQ scans, are used by doctors to look for pulmonary embolism. The most common reason to order a VQ scan is to avoid the IV dye. The IV dye used for CT scans can cause kidney problems in some patients, called contrast-induced nephropathy or "CIN." This is a kidney problem that usually does not make patients feel any differently or change how they urinate. Most of the time, it can only be found by testing blood several days later. This kind of kidney problem can be very mild and some patients will never have any symptoms, rarely these problems can be severe. Some patients can also have similar kidney problems for many other reasons (reactions to medications, blood pressure problems, etc.) and can even happen in patients that do not get IV dye. That is why doctors are not sure exactly who will have these problems or if using a test that does not use IV dye can prevent this kidney problem. The VQ scan uses a different medication through the IV that is not IV dye and has not been linked to kidney problems. The purpose of this study is to learn if using the test that does not use IV dye (the "VQ scan") instead of a CT scan in some patients can help to prevent kidney problems.

Primary Outcome

Count of participants with a creatinine increase ≥ 0.3 mg/dL or 1.5 times baseline.

Interventions

  • DIAGNOSTIC_TEST V/Q imaging
  • DIAGNOSTIC_TEST Computed tomography scan

Trial Details

FieldValue
Enrollment Target 253 participants
Start Date 2017-07-20
Est. Completion 2024-03-27
Phase NA
Indiana University

890 total trials

Why NCT03116139 stopped before completion

NCT03116139 is an interventional study that assigns participants to a tested intervention. The registered 253 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower).

The record links to 0 conditions, and to 2 interventions - of which V/Q imaging is the first listed.

NCT03116139 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03116139 about?

NCT03116139 is a clinical study titled "Acute Kidney Injury in Patients Undergoing Contrast Exposure: VQ vs. CT". Both, CT scans and VQ scans, are used by doctors to look for pulmonary embolism. The most common reason to order a VQ scan is to avoid the IV dye. The IV dye used for CT scans can cause kidney problems in some patients, called contrast-induced nephropathy or "CIN." This is a kidney problem that usua...

What is the current status of trial NCT03116139?

This trial is currently terminated. It is a NA study. The enrollment target is 253 participants. The study started on 2017-07-20. Estimated completion is 2024-03-27.

What interventions are being tested in trial NCT03116139?

The interventions under investigation include: V/Q imaging (DIAGNOSTIC_TEST), Computed tomography scan (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03116139?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03116139's enrollment target sits among peer trials

253 407th of 2000 higher than 1,594 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04390737 · 254 participants · Phase 1

    Evaluate the Safety and Clinical Activity of HH2853

  • NCT04677647 · 254 participants · NA

    OurChild: A Health IT Solution to Reduce Minority Health Disparities

  • NCT05503797 · 254 participants · Phase 2

    A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • NCT06167317 · 254 participants · Phase 1

    Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03116139, the US trial registry maintained by the National Library of Medicine. NCT03116139 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.